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The LAN blood group system: a review
T. Peyrard
LAN (Langereis) was officially recognized by the International 
Society of Blood Transfusion in 2012 as being the 33rd human blood 
group system. It consists of one single high-prevalence antigen, 
Lan (LAN1). The ABCB6 protein is the carrier of the Lan blood 
group antigen. The ABCB6 gene (chromosome 2q36, 19 exons) 
encodes the ABCB6 polypeptide (ATP-binding cassette protein, 
subfamily B, member 6), known as a porphyrin transporter. 
The exceptional Lan– people do not express ABCB6 (Lan null 
phenotype), owing to several different molecular mechanisms 
affecting ABCB6: frameshift leading to a premature stop codon 
(deletion, insertion, or nonsense mutation of nucleotides); 
missense mutation; or intronic mutation responsible for RNA 
splicing defect. Despite the Lan antigen’s being reported to play 
a key role in erythropoiesis and detoxification of cells, Lan– 
people do not appear to demonstrate susceptibility to any disease 
or seemingly physiologic disorder. Anti-Lan has been described 
as having   variable clinical significance, either for hemolytic 
transfusion reactions (none to severe) or hemolytic disease of the 
fetus and newborn (none to mild). Despite challenging conditions 
caused by the scarcity of Lan– donors worldwide, Lan– blood 
should ideally be given to patients with anti-Lan, especially 
those with a high-titer antibody. Immunohematology 
2013;29:131–135.
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History
In 1962, van der Hart and collaborators described an 
antibody to a high-prevalence red blood cell (RBC) antigen 
responsible for a severe and acute hemolytic transfusion 
reaction.1 The corresponding antigen, Lan, was named for 
the index case, Mr. Langereis (Dutch origin), whose brother 
was also found to be Lan–. The antibody of the proband was 
described to be nonreactive with only one random donor in 
4000 tested in the population of the Netherlands.
Many examples of anti-Lan in people with the rare 
Lan– phenotype were later reported.2–10 Two high-prevalence 
antigens, Gna and So, described in 1969 and 1970, respectively, 
were subsequently shown to be the same as Lan.4,11–13
Terminology and Nomenclature
In 1990, the Working Party on Terminology for Red 
Cell Surface Antigens of the International Society of Blood 
Transfusion (ISBT) decided to place Lan in the 901 series 
of RBC antigens, with reference number 901.002.14 The 
901 series corresponds to a family of RBC antigens with a 
prevalence greater than 90 percent in the general population, 
for which data about their genetic independence from other 
known blood group antigens and about their molecular basis 
are nonexistent.15
As a result of the discovery of its molecular basis in 
January 2012 by Helias and collaborators,16 LAN was officially 
moved in July 2012 from the 901 series to the novel 33rd blood 
group system, LAN, by the ISBT Working Party on Red Cell 
Immunogenetics and Blood Group Terminology (ISBT World 
Meeting, Cancun, Mexico).17 The LAN blood group system 
contains one single antigen to date, LAN1.
Genetics and Inheritance
Lan is a high-prevalence antigen in most populations 
(> 99.9%), and Lan– is considered a rare blood type 
worldwide.18,19 Prevalence of the Lan– type was estimated to 
be approximately 1 in 20,000 in Caucasians,18,20 1 in 50,000 in 
Japanese,6 and 1 in 1500 in black people from South Africa.8 
Anti-Lan has also been described in two African Americans.3,10 
The Lan– phenotype is inherited as a recessive character.
In France, 10 of the 29 Lan– people (35%) registered in 
the national rare blood database originate from the Maghreb 
area in North Africa (unpublished observations).
Molecular Basis of Lan
Helias and collaborators16 used a monoclonal anti-Lan 
available from a Japanese team, clone OSK43,21 to elucidate 
the molecular basis of Lan (of note, no commercial anti-Lan 
typing reagent is available on the market). A biochemical 
approach, combining an immunoprecipitation test and mass 
spectrometry analysis, showed that the ABCB6 transporter 
carries the Lan antigen.
The adenosine triphosphate (ATP)-binding cassette 
(ABC) superfamily represents the largest and most broadly 
expressed class of proteins in all kingdoms of life.22 ABC 
proteins are able to transport a variety of biologic compounds 
through ATP hydrolysis. ABCB6 (initially named MTABC3 
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for mammalian-mitochondrial ABC protein 3) is an ATP-
binding cassette molecule, subfamily B, member 6, known 
as a porphyrin transporter, which was initially described to 
be located in the outer membrane of mitochondria.23,24 It was 
later reported that ABCB6 expression could be restricted to 
the Golgi apparatus,25 lysosomes, and plasma membranes.26 
However, this appears controversial because ABCB6 was 
recently purified from mitochondrial membrane extracts.27 
Until the discovery of the molecular basis of LAN, ABCB6 was 
quite surprisingly not reported to be present in the erythrocyte 
membrane.
The ABCB6 gene is located on chromosome 2q36. It spans 
approximately 9.2 kb of genomic DNA, consists of 19 exons 
(3021-bp cDNA; GenBank access number NM_005689; 
Entrez Gene ID 10058), and encodes an 842 multipass 
amino acid protein (80 kDa), ABCB6, with eight membrane-
spanning α-helices.28 ABCB6 belongs to the so-called half-
transporter family within ABC transporters; it contains one 
transmembrane domain (TMD) and one nucleotide-binding 
domain (NBD; Fig 1). The NBD domain binds and hydrolyzes 
ATP; it is located at the C-terminal end of the ABCB6 poly-
peptide and includes three characteristic motifs: an LSGGQ 
conserved signature sequence (specific to ABC transporters)29 
flanked by Walker A and Walker B consensus motifs (common 
to many nucleic acid–dependent ATPases).30 The minimal 
functional molecular unit of ABCB6 has been suggested to be a 
homodimer.23,31 Because ABCB6 has been proposed to regulate 
heme synthesis by shuttling coproporphyrinogen III from the 
cytoplasm into the mitochondria, it is believed to play a crucial 
role in erythropoiesis.23,27,32 ABCB6 has also been reported to 
represent a protective mechanism against oxidative cellular 
stress.33 Finally, ABCB6 has been suggested to be involved in 
cell growth and proliferation by targeting the cell cycle.34
The precise role of ABCB6 in the RBC membrane remains 
unclear. Because the plasma level of porphyrins was found 
to be very low in four Lan– individuals, ABCB6 is thought 
to export porphyrins out of RBCs, which may prevent their 
intracellular accumulation.16
People with the rare Lan– phenotype are actually Lan 
null or ABCB6–/– (two nonfunctional ABCB6 alleles) and may 
therefore be considered as “human knockouts” for ABCB6. 
Lan– individuals demonstrate different inactivating molecular 
mechanisms of ABCB6 at homozygous or compound 
heterozygous states: frameshift leading to a premature stop 
codon (deletion, insertion, or nonsense mutation of nucleotides), 
missense mutation, or intronic mutation responsible for RNA 
splicing defect.
Multiple null alleles of ABCB6 have been reported to date, 
as shown in Table 1. In addition, a few altered alleles of ABCB6 
were recently shown to encode a weak expression of Lan 
(Table 2).35 This may explain why a significant proportion of 
people who are only weakly positive for Lan may be mistyped 
as Lan– if a potent anti-Lan is not used.38
The ISBT has proposed a numbering system for ABCB6 
alleles encoding for null and altered phenotypes (see Web site 
Names for LAN Blood Group Alleles v2.0 130208 http://www.
isbtweb.org/fileadmin/user_upload/WP_on_Red_Cell_
Immunogenetics_and/LAN_Alleles_v2_0__130211.pdf). 
The reference allele encoding Lan is named ABCB6*01. As of 
today, ABCB6 null alleles are numbered from ABCB6*01N.01 
to ABCB6*01N.15 (N for null) and altered alleles 
ABCB6*01W.01 to ABCB6*01W.04 (W for weak); for an update, 
see Web site http://www.isbtweb.org/working-parties/red-
cell-immunogenetics-and-blood-group-terminology/blood-
group-terminology/blood-group-allele-terminology/ from the 
ISBT Working Party on Red Cell Immunogenetics and Blood 
Group Terminology.
ABCB6 mutations have been found in some rare genetic 
diseases, such as ocular coloboma,39 autosomal dominant 
familial pseudohyperkalemia,40 and dyschromatosis univer-
salis hereditaria (so called “gain-of-function” mutations).41 
However, all Lan– people reported to date were seemingly 
healthy, experiencing no clinical symptoms of porphyria or 
abnormal complete blood count.16 As a result, ABCB6 is known 
not to be a protein essential for life in humans, and it does not 
appear to be fully required for erythropoiesis.16 An alternative 
pathway for porphyrin transport very likely exists, probably 
through ABCG2,42 another ABC protein that recently has been 
shown to carry the JR blood group sytem antigens.43
Biochemistry and Physiology
LAN shows a wide tissue distribution and has been 
reported to be highly expressed in fetal liver, heart, eye, and 
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Fig. 1 ABCB6 transporter at the red blood cell surface.
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skeletal muscle.44 Cord RBCs show a higher Lan reactivity 
than adult cells.16
Lan is resistant to the treatment of RBCs by papain, ficin, 
trypsin, α-chymotrypsin, dithiothreitol (DTT) 200 mM, 
pronase, neuraminidase, and EDTA/glycine/acid.19
Antibodies in the System and Clinical Significance
Anti-Lan may be stimulated by RBC transfusion or 
pregnancy. No naturally occurring anti-Lan has been 
reported to date.17 Lan alloantibodies are mostly a mix 
of immunoglobulin (Ig) G1 and IgG3, but IgG1 or IgG3 
alone has also been described, as well as IgG2 and IgG4 
components.6,45–47 Anti-Lan may fix complement.1,6,9
One case of autoanti-Lan has been reported in a female 
patient with a mild autoimmune hemolytic anemia.48 Anti-
Lan was reactive 3+ by indirect antiglobulin test. The direct 
antiglobulin test was weakly positive (1+), and anti-Lan could 
be eluted from autologous RBCs. The patient’s RBCs showed a 
significant weakening of Lan expression.
Anti-Lan has been described as having variable clinical 
significance.18–20,49 It may cause hemolytic transfusion 
reactions, ranging from none to severe,1 and hemolytic disease 
of the fetus and newborn, ranging from none to mild.7,9,50 The 
ability of anti-Lan to cause hemolytic transfusion reaction may 
be studied by in vitro functional assays, and many examples 
of anti-Lan were found to have the potential to destroy Lan+ 
RBCs in vivo.45,49 The reactivity of anti-Lan was reported to 
often be enhanced in the in-vitro monocyte monolayer assay 
when fresh serum is added to anti-Lan at the time of the test.51
Despite challenging conditions caused by scarcity of 
Lan– donors worldwide,52,53 Lan– RBC units should ideally 
be selected for the transfusion of Lan– patients with anti-Lan, 
especially those with a high-titer antibody.54
Table 1. List of reported ABCB6 null alleles that encode the Lan– phenotype18,35
Nucleotide change Location Predicted protein change Ethnic background References
Allele number  
proposed by ISBT
c.197_198insG Exon 1 p.Ala66Gly fs stop Caucasian Helias et al.16 ABCB6*01N.01
c.85_87delTTC Exon 1 p.Phe29del Caucasian Saison et al.36 ABCB6*01N.14
c.376delG Exon 1 p.Val126Ser fs stop African Reid et al.,35 Zelinski et al.37 ABCB6*01N.15
c.574C>T Exon 2 Arg192Trp North African Saison et al.,36 Reid et al.,35 
Zelinski et al.37
ABCB6*01N.13
c.717G>A Exon 3 p.Gln239 stop Caucasian Helias et al.16 ABCB6*01N.02
c.953_956delGTGG Exon 4 p.Gly318Ala fs stop Caucasian Helias et al.16 ABCB6*01N.03
c.1236G>A Exon 6 p.Trp412 stop African Reid et al.,35 Zelinski et al.37 ABCB6*01N.11
c.1533_1543dupCGGCTCCCTGC Exon 9 p.Leu515Pro fs stop Caucasian Helias et al.16 ABCB6*01N.04
c.1558_1559insT Exon 9 p.Val520Cys fs stop Unknown Reid et al.,35 Zelinski et al.37 ABCB6*01N.12
c.1709_1710delAG Exon 11 p.Glu570Gly fs stop Caucasian Helias et al.16 ABCB6*01N.05
c.1690_1691delAT Exon 11 p.Met564Val fs stop Japanese Helias et al.16 ABCB6*01N.06
c.1867delinsAACAGGTGA Exon 14 p.Gly623Asn fs stop Caucasian Helias et al.16 ABCB6*01N.07
c.1942C>T Exon 14 p.Arg648 stop Caucasian Helias et al.16 ABCB6*01N.08
c.1985_1986delTC Exon 15 p.Leu662Pro fs stop Caucasian Helias et al.16 ABCB6*01N.09
c.2256 + 2t>g Intron 16 RNA splicing defect Caucasian Helias et al.16 ABCB6*01N.10
Table 2. List of reported ABCB6 alleles that encode the Lan weak phenotype18,35
Nucleotide change Location Predicted protein change Ethnic background References
Allele number  
proposed by ISBT
c.826C>T Exon 3 p.Arg276Trp Caucasian Reid et al.,35 Saison et al.,36 
Zelinski et al.37
ABCB6*01W.01
c.1028G>A Exon 5 p.Arg343Gln African Reid et al.,35 Zelinski et al.37 ABCB6*01W.02
c.1762G>A Exon 12 p.Gly588Ser Caucasian Reid et al.,35 Saison et al.,36 
Zelinski et al.37
ABCB6*01W.03
c.2216G>A Exon 16 p.Arg739His Hispanic Reid et al.,35 Zelinski et al.37 ABCB6*01W.04
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Summary and Perspectives
The ABCB6 protein recently has been shown to carry the 
Lan antigen. The new system LAN (Langereis), number 33 
according to ISBT, currently contains one single antigen, Lan 
(LAN1), with a prevalence greater than 99.9 percent in most 
populations. Lan– (LAN:–1) people do not express ABCB6 (Lan 
null phenotype). LAN remains a difficult blood group system 
to investigate because no commercial anti-Lan is available 
and no routine molecular testing exists for Lan genotyping. 
Implementation of Lan typing in the currently available high-
throughput genotyping devices will be quite challenging 
because of the high number of null alleles of ABCB6 to be 
simultaneously tested (15 reported to date). In addition, full 
sequencing of ABCB6 is costly and labor intensive (19 exons). 
The so-called next-generation sequencing platforms will likely 
be helpful to overcome this problem in the future. Finally, the 
LAN blood group system, as well as JR,55 turns out to be a 
typical and striking example of the quite unexpected close 
relationships between the immunohematology, pharmacology, 
and oncology fields.
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